

80 Rec'd PCT/PTO 20 JAN 1998

154-130

I hereby certify that this correspondence is being deposited with  
the United States Postal Service as first-class mail in an envelope  
addressed to: Assistant Commissioner for Patents and Trademarks, Washington,  
D.C. 20231 on this 15th day of Jan, 1998.  
By John F. Hoffert

#  
3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----  
MICHAEL LEBRUN ET AL )  
SERIAL NO. 08/945,144 )  
INTERNATIONAL APPLN.: PCT/FR96/01125 )  
INTERNATIONAL FILING DATE: 7/18/96 ) BOX PCT  
FILED: OCTOBER 14, 1997 )  
FOR: MUTATED 5-ENOL PYRUVYLSHIKI- )  
MATE-3-PHOSPHATE SYNTHASE, GENE )  
CODING FOR SAID PROTEIN AND TRANS- )  
FORMED PLANTS CONTAINING SAID GENE )  
-----

Assistant Commissioner for Patents  
Washington, D.C. 20231

COMPLETION OF APPLICATION FORMALITIES

Sir:

Enclosed herewith are the following:


- A copy of the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US).
- Check for the surcharge (\$130.00) under 37 CFR 1.492(e).
- A Petition for Extension under 37 CFR 1.136(a) and Check for the applicable fee.
- An executed Declaration & Power of Attorney, signed by the inventor(s), which references the application as filed.

The Commissioner is hereby authorized to charge any additional fees, or credit any overpayment to, Deposit Account No. 03-2775. This paper is submitted in duplicate.

Respectfully Submitted,

CONNOLLY AND HUTZ

By:

  
Robert G. McMorrow, Jr.  
Registration No. 30,962  
Telephone No. (302) 658-9141

23858

08/945144

108 Rec'd PCT/PTO Atty. Docker RE/MPD 14 OCT 1997

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**INTERNATIONAL APPL. NO.: PCT/FR96/01125 :**

**INTERNATIONAL FILING DATE: 07/18/96 :**

**APPLICANT: MICHEL LEBRUN ET AL :**

**SERIAL NO: : ART UNIT:**

**FILED: : EXAMINER:**


**FOR: "MUTATED 5-ENOL PYRUVYLSHIKI-MATE-3-PHOSPHATE SYNTHASE, GENE CODING FOR SAID PROTEIN AND TRANSFORMED PLANTS CONTAINING SAID GENE" :**

**Hon. Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231**

"Express Mail" No.: EI841020925 US Date: OCTOBER 14, 1997

I hereby certify that this paper, along with any other paper or fee referred to in this paper as being transmitted herewith, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10, postage prepaid, on the date indicated above, addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231

-Ann F. Griffith -  
(Typed or printed name of mailing paper or fee)

  
(Signature of person mailing paper)

**TRANSMITTAL OF APPLICATION PAPERS  
TO U.S. DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. §371  
(CFR 1.494 OR 1.495)**

This Transmittal Letter is based upon PTO Form 1390 (as revised in May, 1993).

The above-identified applicant(s) (jointly with their assignee) have filed an International Application under the P.C.T. and hereby submit(s) to the United States Designated/Elected Office (DO/EO/US) the following items and other information.

1.  This is a **FIRST** submission of items concerning a filing under 35 U.S.C. §371.
2.  This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. §371.
3.  This is an express request to begin national examination procedures (35 U.S.C. §371[f]) at any time rather than delay.
4.  A proper Demand for International Preliminary Examination (IPE) was made to the appropriate Authority (IPEA) by the 19th month from the earliest claimed priority date.
5.  A copy of the International Application as filed (35 U.S.C. §371[c][2]) --
  - a.  is transmitted herewith (required when not transmitted by International Bureau). See WIPO Publication WO 97/04103.
  - b.  has been transmitted by the International Bureau.
  - c.  is not required, as the application was filed in the United States Receiving Office (RO/US).
6.  A (verified) translation of the International Application into the English language is enclosed.
7.  Amendments to the (specification and) claims of the International Application under PCT Article 19 (35 U.S.C. 371[c][3])
  - a.  are transmitted herewith (required if not transmitted by the International Bureau).
  - b.  have been transmitted by the International Bureau.
  - c.  have not been made; however, the time limit for making such amendments has NOT expired.
  - d.  have not been made and will not be made.
  - e.  will be submitted with the appropriate surcharge.
8.  A translation of the amendments to the claims (and/or the specification) under PCT Article 19 (35 U.S.C. §371[c][3]) is enclosed or will be submitted with the appropriate surcharge.

9.  An oath or declaration/power of attorney of the inventor(s) (35 U.S.C. §371[c][4]) will follow.  
[ ] and is attached to the translation of (or a copy of) the International Application.  
[ ] and is attached to the substitute specification.
10.  A translation of at least the Annexes to the IPE Report under PCT Article 36 (35 U.S.C. §371[c][5]) will follow.

Items 11. to 16. below concern other document(s) or information included:

11. [ ] An Information Disclosure Statement under 37 CFR 1.97 and 1.98 is enclosed.
12.  An Assignment will follow for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 will follow.
13.  A FIRST preliminary amendment is enclosed.  
A SECOND or SUBSEQUENT preliminary amendment is enclosed.
14. [ ] A substitute specification (including claims, abstract, drawing) is enclosed.
15. [ ] A change of power of attorney and/or address letter is enclosed.
16.  Other items of information:

This application is being filed pursuant to 37 CFR 1.494(c) or 1.495(c), and any missing parts will be filed before expiration of--

22 months from the priority date under 37 CFR 1.494(c), or

32 months from the priority date under 37 CFR 1.495(c).

The undersigned attorney is authorized by the International applicant and by the inventors to enter the National Phase pursuant to 37 CFR 1.494(c) or 1.495(c).

The following additional information relates to the International Application:

- Receiving Office: France
- IPEA (if filing under 37 CFR 1.495): EPO
- Priority Claim(s) (35 USC §§ 119, 365):  
French Appln. 95/08979 filed July 19, 1995.
- A copy of the International Search Report is

[ ] enclosed.

attached to the copy of the English Translation of the International Application.

[ ] A copy of the Receiving Office Request Form is enclosed.

The fee calculation is set forth on the next page of this Transmittal Letter.

## FEE CALCULATION SHEET

A check in payment of the filing fee, calculated as follows, is attached (37 CFR 1.492).

Basic Fee..... \$ 930.00

Total Number of claims in  
excess of (20) times \$22.....

Number of independent claims  
in excess of (3) times \$82..... -0-


Fee for multiple dependent  
claims \$270..... -0-

TOTAL FILING FEE... \$ 930.00

Kindly send us the official filing receipt.

The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Deposit Account No. 03-2775. This is a "general authorization" under 37 CFR 1.25(b), except that no automatic debit of the issue upon allowance is authorized. An additional copy of this page is attached.

Respectfully submitted,

By   
\_\_\_\_\_  
ROBERT G. McMORROW, JR.

Reg. No. 30,962  
CONNOLLY & HUTZ  
1220 Market Street  
P.O. Box 2207  
Wilmington, Delaware 19899  
Tel. (302) 658-9141

To Follow:

Declaration  
Assignment  
Trans. of IPEA Report  
into English

RGM/afg  
Enclosures  
Specification and Claims  
Preliminary Amendment  
Check for \$930.00  
Copy of Notification of Additional Inventor  
Copy of Demand (Ch.II)/ 5  
Acceptance  
IPEA REPORT (In French)  
WIPO NOTICE (PCT/IB/332)

08/945144  
41 Rec'd PCT/PTO 14 OCT 1997

RP/PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

MICHEL LEBRUN ET AL

:

SERIAL NO:

: ART UNIT:

FILED:

: EXAMINER:

FOR: "MUTATED 5-ENOL  
PYRUVYL SHIKIMATE-3-PHOSPHATE SYNTHASE,  
GENE CODING FOR SAID PROTEIN AND  
TRANSFORMED PLANTS CONTAINING SAID  
GENE"

:


Hon. Commissioner of Patents  
& Trademarks  
Washington, D.C. 20231

:

"Express Mail" No.: EI841020925 Date: OCTOBER 14, 1997

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231

- ANN F. GRIFFITH -  
(Typed or printed name) of  
person mailing paper or fee)

  
(Signature of person  
mailing paper or fee)

PRELIMINARY AMENDMENT

Sir:

Prior to any action on the merits of the accompanying new patent application, kindly amend the application as follows:

In the Claims:

Claim 5, lines 1 and 2, change "one of claims 1 to 4" to read -- claim 1 -- ;

RP/PCT

**Claim 7**, lines 1 and 2, change "one of claims 1 to 4"  
to read -- claim 1 -- ;

**Claim 10**, line 6, change "one of claims 1 to 8" to read  
-- claim 1 -- ;

**Claim 13**, line 3, change "one of claims 10 to 12" to  
read -- claim 10 -- ;

**Claim 14**, lines 2 and 3, change "one of claims 10 to 12"  
to read -- claim 10 -- ;

**Claim 16**, line 5, change "one of claims 1 to 8" to read  
-- claim 1 -- .

R E M A R K S

**Claims 5, 7, 10, 13, 14 and 16** have been amended to refer  
to only one preceding claim. Each of the dependent claims, as  
amended, now depends on only one preceding claim. Therefore  
no additional fee is required for multiple dependency.

Prompt, favorable action is solicited.

Respectfully submitted,

CONNOLLY AND HUTZ

By

Robert G. McMorrow, Jr., Reg. No. 30,962  
P.O. Box 2207  
Wilmington, Delaware 19899  
(302) 658-9141  
Attorney for Applicants

RGM/afg  
(5500\*13)

08/945144  
41 Rec'd PCT/PTO 14 OCT 1997

MUTATED 5-ENOL  
PYRUVYLSHIKIMATE-3-PHOSPHATE SYNTHASE,  
GENE CODING  
FOR SAID PROTEIN  
AND TRANSFORMED PLANTS  
CONTAINING SAID GENE

Michel Lebrun  
Alain Sailland  
Georges Freyssinet  
and  
Eric DeGryse

INTERNATIONAL APPLICATION  
IN ENGLISH  
including  
SEARCH REPORT

RP/PCT

PCT/FR96/01125

.....

IFD: 07/18/96

"Express Mail" mailing label number <b>FE1841020925 IIS</b>
Date of Deposit <u>October 14, 1997</u>
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231
<b>ANN F. GRIFFITH</b>
(Typed or Printed name of person mailing paper or fee)
<i>Ann F. Griffith</i>

Mutated 5-enolpyruvylshikimate-3-phosphate synthase,  
gene coding for this protein and transformed plants  
containing this gene

The present invention relates to a new

5      5-enolpyruvylshikimate-3-phosphate synthase (or EPSPS)  
which displays increased tolerance with respect to  
herbicides which are competitive inhibitors with  
respect to phosphoenolpyruvate (PEP) of EPSPS activity.  
This more tolerant EPSPS synthase possesses at least one  
10     "threonine by isoleucine" substitution. The invention  
also relates to a gene coding for such a protein, to  
plant cells transformed by chimeric gene constructions  
containing this gene, to the plants regenerated from  
these cells and also to the plants originating from  
15     crossing using these transformed plants.

Glyphosate, sulfosate and fosametine are  
broad-spectrum systemic herbicides of the  
phosphonomethylglycine family. They act essentially as  
competitive inhibitors of 5-enolpyruvylshikimate-3-  
20     phosphate synthase (EC 2.5.1.19) or EPSPS with respect  
to the PEP (phosphoenolpyruvate). After their  
application to the plant, they are translocated in the  
plant where they accumulate in the rapidly growing  
parts, in particular the caudine and root apices,  
25     causing damage to the point of destruction of sensitive  
plants.

Plastid EPSPS, the main target of these

products, is an enzyme of the pathway of biosynthesis of aromatic amino acids, which is encoded by one or more nuclear genes and synthesized in the form of a cytoplasmic precursor, then imported into the plastids 5 where it accumulates in its mature form.

The tolerance of plants to glyphosate and to products of the family is obtained by stable introduction into their genome of an EPSPS gene, of plant or bacterial origin, which is mutated or 10 otherwise in respect of the characteristics of inhibition by glyphosate of the product of this gene. In view of the mode of action of glyphosate and the degree of tolerance to glyphosate of the product of the genes which are used, it is advantageous to be able to 15 express the product of the translation of this gene so as enable it to be accumulated in substantial amounts in the plastids.

It is known, for example from US Patent 4,535,060, to confer on a plant a tolerance to a 20 herbicide of the above type, especially N-phosphono-methylglycine or glyphosate, by introducing into the genome of plants a gene coding for an EPSPS carrying at least one mutation that makes this enzyme more resistant to its competitive inhibitor (glyphosate) 25 after localization of the enzyme in the plastid compartment. These techniques, however, need to be improved in order to obtain greater reliability in the use of these plants under agricultural conditions.

In the present description, "plant" is understood to mean any differentiated multicellular organism capable of photosynthesis, and "plant cell" is understood to mean any cell originating from a plant  
5 and capable of constituting undifferentiated tissues such as calluses or differentiated tissues such as embryos or plant parts or seeds.

The subject of the present invention is the production of transformed plants having increased  
10 tolerance to herbicides of the phosphonomethylglycine family, by regeneration of cells transformed by means of new chimeric genes containing a gene for tolerance to these herbicides.

The subject of the invention is also a  
15 chimeric gene for conferring on plants increased tolerance with respect to a herbicide having EPSPS as its target, comprising, in the direction of transcription: a promoter region, optionally a transit peptide region, a sequence of a gene coding for a  
20 glyphosate tolerance enzyme and an untranslated polyadenylation signal region at the 3' end, characterized in that the glyphosate tolerance gene contains, relative to the gene from which it is derived, a "threonine 102 by isoleucine" substitution  
25 in the "aroA" (EPSPS) region. Preferably, it comprises, in addition, in the same region, a "proline 106 by serine" substitution. These substitutions can be introduced or be present in an EPSPS sequence of any

origin, in particular of plant, bacterial, algal or fungal origin.

The transit peptides which can be used in the transit peptide region can be, known per se, of plant origin, for example originating from maize, sunflower, pea, tobacco or the like. The first and the second transit peptide can be identical, similar or different. They can, in addition, each comprise one or more transit peptide units according to European Patent Application EP 0 508 909. It is the role of this characteristic region to permit the release of a mature and native protein, and especially the above mutated EPSPS, with maximum efficacy in the plasmid compartment.

The promoter region of the chimeric gene according to the invention may be advantageously composed of at least one gene promoter or promoter fragment which is expressed naturally in plants (tubulin, introns, actin, histone).

The untranslated transcription termination signal region at the 3' end of the chimeric gene may be of any origin, for example of bacterial origin, such as that of the nopaline synthase gene, or of plant origin, such as that of the *Arabidopsis thaliana* histone H4A748 gene according to the European Patent Application (European Application 633 317).

The chimeric gene according to the invention can comprise, in addition to the essential portions

above, at least one untranslated intermediate (linker) region, which can be located between the different transcribed regions described above. This intermediate region can be of any origin, for example of bacterial,  
5 viral or plant origin.

Isolation of a cDNA coding for a maize EPSPS:

The different steps which led to the obtaining of maize EPSPS cDNA, which served as substrate for the introduction of the two mutations,  
10 are described below. All the operations described below are given by way of example, and correspond to a choice made from among the different methods available for arriving at the same result. This choice has no effect on the quality of the result, and consequently any  
15 suitable method may be used by a person skilled in the art to arrive at the same result. Most of the methods of engineering of DNA fragments are described in "Current Protocols in Molecular Biology" Volumes 1 and 2, Ausubel F.M. et al., published by Greene Publishing  
20 Associates and Wiley-Interscience (1989) (hereinafter, references to protocols described in this work will be designated "ref. CPMB"). The operations relating to DNA which were performed according to the protocols described in this work are especially the following:  
25 ligation of DNA fragments, treatment with Klenow DNA polymerase and T4 DNA polymerase, preparation of plasmid and of bacteriophage  $\lambda$  DNA, either as a minipreparation or as a maxipreparation, and DNA and

RNA analyses according to the Southern and Northern techniques, respectively. Other methods described in this work were followed, and only significant modifications or additions to these protocols have been  
5 described below.

Example 1:

1. Obtaining of an *Arabidopsis thaliana* EPSPS fragment

a) Two 20-mer oligonucleotides of respective  
10 sequences:

5' -GCTCTGCTCATGTCTGCTCC-3'

5' -GCCCGCCCTTGACAAAGAAA-3'

were synthesized from the sequence of an *Arabidopsis thaliana* EPSPS gene (Klee H.J. et al. (1987) Mol. Gen. 15 Genet., 210, 437-442). These two oligonucleotides are at positions 1523 to 1543 and 1737 to 1717, respectively, of the published sequence, and in opposite orientations.

b) *Arabidopsis thaliana* (var. *columbia*) total  
20 DNA was obtained from Clontech (catalogue reference:  
6970-1).

c) 50 nanograms (ng) of DNA are mixed with  
300 ng of each of the oligonucleotides and subjected to  
35 amplification cycles with a Perkin-Elmer 9600  
25 apparatus, under the conditions of standard medium for  
amplification which are recommended by the supplier.  
The resulting 204-bp fragment constitutes the

*Arabidopsis thaliana EPSPS fragment.*2. Construction of a library of a cDNA from a  
BMS maize cell line

a) 5 g of filtered cells are ground in liquid  
5 nitrogen, and the total nucleic acids are extracted  
according to the method described by Shure et al. with  
the following modifications:

- the pH of the lysis buffer is adjusted  
to pH 9.0;
- 10 - after precipitation with isopropanol,  
the pellet is taken up in water and,  
after dissolution, adjusted to 2.5 M  
LiCl. After incubation for 12 h at °C,  
the pellet from centrifugation for 15  
15 min at 30,000 g at 4°C is  
resolubilized. The LiCl precipitation  
step is then repeated. The resolubilized  
pellet constitutes the RNA fraction of  
the total nucleic acids.

20 b) The poly(A)<sup>+</sup> RNA fraction of the RNA  
fraction is obtained by chromatography on an oligo(dT)-  
cellulose column as described in "Current Protocols in  
Molecular Biology".

c) Synthesis of double-stranded cDNA having a  
25 synthetic EcoRI end: this is carried out according to  
the protocol of the supplier of the different reagents  
needed for this synthesis in the form of a kit: the  
"copy kit" from the company In Vitrogen.

Two single-stranded and partially complementary oligonucleotides of respective sequences:

5'-AATTCCCCGGG-3'

5' -CCCGGG-3' (the latter being  
phosphorylated)

are ligated with the blunt-ended double-stranded cDNAs.

This ligation of the adaptors results in the creation of SmaI sites attached to the double-stranded cDNAs and EcoRI sites in cohesive form at each end of  
10 the double-stranded cDNAs.

d) Creation of the library:

The cDNAs possessing the artificial cohesive EcoRI sites at their ends are ligated with bacteriophage λgt10 cDNA which has been cut with EcoRI  
15 and dephosphorylated according to the protocol of the supplier New England Biolabs.

An aliquot of the ligation reaction was encapsidated in vitro with encapsidation extracts, namely Gigapack Gold, according to the supplier's  
20 instructions; this library was titrated using the bacterium *E. coli* C600hfl. The library thereby obtained is amplified and stored according to the instructions of the same supplier, and constitutes the BMS maize cell suspension cDNA library.

25 3. Screening of the BMS maize cell suspension cDNA library with the *Arabidopsis thaliana* EPSP probe

The protocol followed is that of "Current Protocols in Molecular Biology" Volumes 1 and 2,

Ausubel F.M. et al., published by Greene Publishing  
Associates and Wiley-Interscience (1989) (CPMB).

Briefly, approximately  $10^6$  recombinant phages are plated out on LB dishes at an average density of 100 5 phages/cm<sup>2</sup>. The lytic plaques are replicated in duplicate on Amersham Hybond N membranes.

The DNA was fixed to the filters by 1600kJ UV treatment (Stratagene Stratalinker). The filters were prehybridized in 6xSSC/0.1%SDS/0.25 skimmed milk for 10 2 h at 65°C. The *Arabidopsis thaliana* EPSPS probe was labelled with [<sup>32</sup>P]dCTP by random priming according to the supplier's instructions (Pharmacia Ready to Go kit). The specific activity obtained is of the order of 10<sup>8</sup> cpm per µg of fragment. After denaturation for 15 5 min at 100°C, the probe is added to the prehybridization medium and hybridization is continued for 14 hours at 55°C. The filters are fluorographed for 20 48 h at -80°C with Kodak XAR5 film and Amersham Hyperscreen RPN enhancing screens. Alignment of the positive spots on the filter with the dishes from which they originate enables zones corresponding to the 25 phages displaying a positive hybridization response with the *Arabidopsis thaliana* EPSPS probe to be picked out from the dish. This step of plating out, transfer, hybridization and recovery is repeated until all the spots in the dish of the successively purified phages prove 100% positive in hybridization. An independent plaque of phage lysis is then picked out in diluent λ

medium (Tris-Cl pH 7.5; 10mM MgSO<sub>4</sub>; 0.1M NaCl; 0.1% gelatin); these phages in solution constitute the EPSP-positive clones of the BMS maize cell suspension.

4. Preparation and analysis of the DNA of the  
5 EPSP clones of the BMS maize cell suspension

Approximately 5x10<sup>8</sup> phages are added to 20 ml of C600hfl bacteria at an OD<sub>600nm</sub> value of 2/ml and incubated for 15 minutes at 37°C. This suspension is then diluted in 200 ml of bacterial growth medium in a  
10 1-l Erlenmeyer and stirred in a rotary stirrer at 250 rpm. Lysis is noted when the medium clarifies, corresponding to the lysis of the turbid bacteria, and takes place after approximately 4 h of stirring. This supernatant is then treated as described in "Current  
15 Protocols in Molecular Biology". The DNA obtained corresponds to the EPSP clones of the BMS maize cell suspension.

One to two µg of this DNA are cut with EcoRI and separated on 0.8% LGTA/TBE agarose gel (ref. CPMB).  
20 A final verification consists in checking that the purified DNA does indeed display a hybridization signal with the *Arabidopsis thaliana* EPSPS probe. After electrophoresis, the DNA fragments are transferred onto Amersham Hybond N membranes according to the protocol  
25 of Southern described in "Current Protocols in Molecular Biology". The filter is hybridized with the *Arabidopsis thaliana* EPSPS probe according to the conditions described in section 3 above. The clone

displaying a hybridization signal with the *Arabidopsis thaliana* EPSPS probe and containing the longest EcoRI fragment has a size estimated on gel as approximately 1.7 kbp.

5

### 5. Obtaining of the clone pRPA-ML-711

Ten µg of the phage clone containing the 1.7-kbp insert are digested with EcoRI and separated on 0.8% LGTA/TBE agarose gel (ref. CPMB). The gel fragment containing the 1.7-kbp insert is excised from the gel 10 by BBT staining, and the fragment is treated with  $\beta$ -agarase according to the protocol of the supplier, New England Biolabs. The purified DNA of the 1.7-kbp fragment is ligated at 12°C for 14 h with the DNA of plasmid pUC 19 (New England Biolabs) cut with EcoRI 15 according to the ligation protocol described in "Current Protocols in Molecular Biology". Two µl of the above ligation mixture are used for the transformation of an aliquot of electrocompetent *E. coli* DH10B; transformation is accomplished by electroporation using 20 the following conditions: the mixture of competent bacteria and ligation medium is introduced into an electroporation cell of thickness 0.2 cm (Biorad) previously cooled to 0°C. The physical conditions of the electroporation using an electroporator made by 25 Biorad are 2500 volts, 25 µF and 200 Ω. Under these conditions, the mean discharge time of the condenser is of the order of 4.2 milliseconds. The bacteria are then taken up in 1 ml of SOC medium (ref. CPMB) and stirred

for 1 hour at 200 rpm on a rotary stirrer in 15-ml Corning tubes. After plating out on LB/agar medium supplemented with 100 µg/ml of carbenicillin, minipreparations of the bacterial clones which have grown after one night at 37°C are produced according to the protocol described in "Current Protocols in Molecular Biology". After digestion of the DNA with EcoRI and separation by electrophoresis on 0.8% LGTA/TBE agarose gel (ref. CPMB), the clones possessing a 1.7-kbp insert are retained. A final verification consists in checking that the purified DNA does indeed display a hybridization signal with the *Arabidopsis thaliana* EPSPS probe. After electrophoresis, the DNA fragments are transferred onto Amersham Hybond N membranes according to the protocol of Southern described in "Current Protocols in Molecular Biology". The filter is hybridized with the *Arabidopsis thaliana* EPSPS probe according to the conditions described in section 3 above. The plasmid clone possessing a 1.7-kbp insert and hybridizing with the *Arabidopsis thaliana* EPSPS probe was prepared on a larger scale, and the DNA resulting from the lysis of the bacteria was purified on a CsCl gradient as described in "Current Protocols in Molecular Biology". The purified DNA was partially sequenced with a Pharmacia kit according to the supplier's instructions and using as primers the M13 direct and reverse universal primers ordered from the same supplier. The partial sequence produced covers

approximately 0.5 kbp. The derived amino acid sequence in the region of the mature protein (approximately 50 amino acid residues) displays 100% identity with the corresponding amino sequence of mature maize EPSPS described in American Patent USP 4,971,908. This clone, corresponding to a 1.7-kbp EcoRI fragment of the EPSP DNA of the BMS maize cell suspension, was designated pRPA-ML-711. The complete sequence of this clone was determined on both strands using the protocol of the Pharmacia kit and synthesizing complementary oligonucleotides and those of the opposite orientation every 250 bp approximately. The complete sequence obtained of this 1713-bp clone is presented in SEQ ID No. 1.

15           6. Obtaining of the clone pRPA-ML-715

Analysis of the sequence of the clone pRPA-ML-711, and especially comparison of the derived amino acid sequence with that of maize, shows a sequence extension of 92 bp upstream of the GCG codon coding for the NH<sub>2</sub>-terminal alanine of the mature portion of maize EPSPS (American Patent USP 4,971,908). Similarly, an extension of 288 bp downstream of the AAT codon coding for the COOH-terminal asparagine of the mature portion of maize EPSPS (American Patent USP 4,971,908) is observed. These two portions could correspond, in the case of the NH<sub>2</sub>-terminal extension to a portion of the sequence of a transit peptide for plastid localization, and, in the case of the COOH-terminal extension, to the

untranslated 3' region of the cDNA.

In order to obtain a cDNA coding for the mature portion of the maize EPSPS cDNA, as described in USP 4,971,908, the following operations were carried  
5 out:

a) Removal of the untranslated 3' region:  
construction of pRPA-ML-712:

The clone pRPA-ML-711 was cut with the restriction enzyme AseI, and the ends resulting from  
10 this cleavage were rendered blunt by treatment with the Klenow fragment of DNA polymerase I according to the protocol described in CPMB. A cleavage with the restriction enzyme SacII was then performed. The DNA resulting from these operations was separated by  
15 electrophoresis on 1% LGTA/TBE agarose gel (ref. CPMB).

The gel fragment containing the 0.4-kbp "AseI-blunt ends/SacII" insert was excised from the gel and purified according to the protocol described in section 5 above. The DNA of the clone pRPA-ML-711 was  
20 cut with the restriction enzyme HindIII at the HindIII site located in the polylinker of the cloning vector pUC19, and the ends resulting from this cleavage were rendered blunt by treatment with the Klenow fragment of DNA polymerase I. A cleavage with the restriction  
25 enzyme SacII was then performed. The DNA resulting from these manipulations was separated by electrophoresis on 0.7% LGTA/TBE agarose gel (ref. CPMB).

The gel fragment containing the approximately

3.7-kbp HindIII-blunt ends/BacII insert was excised from the gel and purified according to the protocol described in section 5 above.

The two inserts were ligated, and 2  $\mu$ l of the  
5 ligation mixture were used to transform *E. coli* DH10B  
as described above in section 5.

The plasmid DNA content of different clones was analysed according to the procedure described for pRPA-ML-711. One of the plasmid clones selected  
10 contains an approximately 1.45-kbp EcoRI-HindIII insert. The sequence of the terminal ends of this clone reveals that the 5' end of the insert corresponds exactly to the corresponding end of pRPA-ML-711, and that the 3'-terminal end possesses the following  
15 sequence:

"5' -...AATTAAGCTCTAGAGTCGACCTGCAGGCATGCCAAGCTT-3'".

The underlined sequence corresponds to the codon of the COOH-terminal amino acid asparagine, the next codon corresponding to the translation stop codon.  
20 The nucleotides downstream correspond to sequence elements of the pUC19 polylinker. This clone comprising the pRPA-ML-711 sequence up to the translation termination site of mature maize EPSPS and followed by sequences of the pUC 19 polylinker up to the HindIII site was designated pRPA-ML-712.  
25

b) Modification of the 5' end of pRPA-ML-712:  
construction of pRPA-ML-715:

The clone pRPA-ML-712 was cut with the

restriction enzymes *Pst*I and *Hind*III. The DNA resulting from these manipulations was separated by electrophoresis on 0.8% *LGTA/TBE* agarose gel (ref. CPMB). The gel fragment containing the 1.3-kbp *Pst*I-  
5 *Eco*RI insert was excised from the gel and purified according to the protocol described in section 5 above. This insert was ligated in the presence of an equimolecular amount of each of the two partially complementary oligonucleotides of sequence:  
10 Oligo 1: 5'-GAGCCGAGCTCCATGGCCGGCGCCGAGGAGATCGTGCTGCA-3'  
Oligo 2: 5'-GCACGATCTCCTCGCGGCCGGCATGGAGCTCGGCTC-3'  
as well as in the presence of plasmid pUC19 DNA digested with the restriction enzymes *Bam*HI and *Hind*III.  
15 Two  $\mu$ l of the ligation mixture were used to transform *E. coli* DH10B as described above in section 5. After analysis of the plasmid DNA content of different clones according to the procedure described above in section 5, one of the clones possessing an  
20 approximately 1.3-kbp insert was retained for subsequent analyses. The sequence of the 5'-terminal end of the selected clone reveals that the DNA sequence in this region is the following: sequence of the pUC19 polylinker from the *Eco*RI to the *Bam*HI sites, followed  
25 by the sequence of the oligonucleotides used in the cloning, followed by the remainder of the sequence present in pRPA-ML-712. This clone was designated pRPA-ML-713. This clone possesses a methionine ATG codon

included in an NcoI site upstream of the N-terminal alanine codon of mature EPSP synthase. Furthermore, the alanine and glycine codons of the N-terminal end have been preserved, but modified on the third variable  
5 base: initial GCGGGT gives modified GCGGGC.

The clone pRPA-ML-713 was cut with the restriction enzyme HindIII, and the ends of this cleavage were rendered blunt by treatment with the Klenow fragment of DNA polymerase I. A cleavage with  
10 restriction enzyme SacI was then performed. The DNA resulting from these manipulations was separated by electrophoresis on 0.8% LGTA/TBE agarose gel (ref. CPMB). The gel fragment containing the 1.3-kbp "HindIII-blunt ends/SacI" insert was excised from the  
15 gel and purified according to the protocol described in section 5 above. This insert was ligated in the presence of plasmid pUC19 DNA digested with restriction enzyme XbaI, and the ends of this cleavage were rendered blunt by treatment with the Klenow fragment of  
DNA polymerase I. A cleavage with the restriction  
20 enzyme SacI was then performed. Two  $\mu$ l of the ligation mixture were used to transform E. coli DH10B as described above in section 5. After analysis of the plasmid DNA content of different clones according to  
25 the procedure described above in section 5, one of the clones possessing an approximately 1.3-kbp insert was retained for subsequent analyses. The sequence of the terminal ends of the selected clone reveals that the

DNA sequence is the following: sequence of the pUC19 polylinker from the EcoRI to SacI sites, followed by the sequence of the oligonucleotides used in the cloning from which the 4 bp GATCC of the 5 oligonucleotide 1 described above have been deleted, followed by the remainder of the sequence present in pRPA-ML-712 up to the HindIII site and sequence of the pUC19 polylinker from XbaI to HindIII. This clone was designated pRPA-ML-715.

10           7. Obtaining of a cDNA coding for a mutated maize EPSPS

All the mutagenesis steps were carried out with the Pharmacia U.S.E. mutagenesis kit according to the supplier's instructions. The principle of this 15 mutagenesis system is as follows: plasmid DNA is denatured by heat and reassociated in the presence of a molar excess of, on the one hand the mutagenesis oligonucleotide, and on the other hand an oligonucleotide enabling a unique restriction enzyme site present in 20 the polylinker to be eliminated. After the reassociation step, synthesis of the complementary strand is carried out by the action of T4 DNA polymerase in the presence of T4 DNA ligase and gene 32 protein in a suitable buffer which is supplied. The 25 synthesis product is incubated in the presence of the restriction enzyme for which the site is assumed to have disappeared by mutagenesis. The *E. coli* strain possessing, in particular, the mutS mutation is used as

host for the transformation of this DNA. After growth in liquid medium, the total plasmid DNA is prepared and incubated in the presence of the restriction enzyme used before. After these treatments, *E. coli* strain 5 DH10B is used as host for the transformation. The plasmid DNA of the clones isolated is prepared, and the presence of the mutation introduced is verified by sequencing.

A)- modification of sites or sequences  
10 without in principle affecting the EPSPS-resistance character of maize to products which are competitive inhibitors of EPSP synthase activity: elimination of an internal NcoI site from pRPA-ML-715.

The pRPA-ML-715 sequence is numbered 15 arbitrarily by placing the first base of the N-terminal alanine codon GCC at position 1. This sequence possesses an NcoI site at position 1217. The site-modification oligonucleotide possesses the sequence:  
20 5' -CCACAGGATGGCGATGGCCTTCTCC-3'.

After sequencing according to the references given above, the sequence read after mutagenesis corresponds to that of the oligonucleotide used. The NcoI site has indeed been eliminated, and the translation into amino acids in this region preserves the initial 25 sequence present in pRPA-ML-715.

This clone was designated pRPA-ML-716.

The 1340-bp sequence of this clone is presented in SEQ ID No. 2 and SEQ ID No. 3.

B) - sequence modifications enabling the EPSPS-resistance character of maize to products which are competitive inhibitors of EPSP synthase activity to be increased.

5 The following oligonucleotides were used:

a) mutation Thr 102 → Ile.

5' -GAATGCTGGAATCGCAATGCCGGCATTGACAGC-3'

b) mutation Pro 106 → Ser.

5' -GAATGCTGGAACTGCAATGCCGGTCCATTGACAGC-3'

10 c) mutations Gly 101 → Ala and Thr 102 → Ile.

5' -CTTGGGGAAATGCTGCCATCGCAATGCCGGCATTG-3'

d) mutations Thr 102 → Ile and Pro 106 → Ser.

5' -GGGAAATGCTGGAATCGCAATGCCGGTCCATTGACAGC-3'

After sequencing, the sequence read after  
15 mutagenesis on the three mutated fragments is identical  
to the parent pRPA-ML-716 DNA sequence, with the  
exception of the mutagenized region which corresponds  
to that of the mutagenesis oligonucleotides used. These  
clones were designated: pRPA-ML-717 for the mutation  
20 Thr 102 → Ile, pRPA-ML-718 for the mutation Pro 106 →  
Ser, pRPA-ML-719 for the mutations Gly 101 → Ala and  
Thr 102 → Ile and pRPA-ML-720 for the mutations Thr 102  
→ Ile and Pro 106 → Ser.

The 1340-bp sequence of pRPA-ML-720 is

presented in SEQ ID No. 4 and SEQ ID No. 5.

The 1395-bp NcoI-HindIII insert is the basis of all the constructions used for the transformation of plants for the introduction of resistance to herbicides which are competitive inhibitors of EPSPS, and especially glyphosate resistance. This insert will be designated in the remainder of the description "the maize EPSPS double mutant".

Example 2:

10           **Glyphosate tolerance of the different mutants  
in vitro**

**2.a: Extraction of EPSP synthase**

The different EPSP synthase genes are introduced in the form of an NcoI-HindIII cassette into 15 the plasmid vector pTrc99a (Pharmacia, ref: 27-5007-01) cut with NcoI and HindIII. Recombinant *E. coli* DH10B bacteria overexpressing the different EPSP synthases are sonicated in 40 ml of buffer per 10 g of pelleted cells, and washed with this same buffer (200 mM Tris- 20 HCl pH 7.8, 50 mM mercaptoethanol, 5 mM EDTA and 1 mM PMSF), to which 1 g of polyvinylpyrrolidone is added. The suspension is stirred for 15 minutes at 4°C and then centrifuged for 20 minutes at 27,000 g and 4°C.

Ammonium sulphate is added to the supernatant 25 to bring the solution to 40% saturation with respect to ammonium sulphate. The mixture is centrifuged for 20 minutes at 27,000 g and 4°C. Ammonium sulphate is added to the new supernatant to bring the solution to

70% saturation with respect to ammonium sulphate. The mixture is centrifuged for 30 minutes at 27,000 g and 4°C. The EPSP synthase present in this protein pellet is taken up in 1 ml of buffer (20 mM Tris-HCl pH 7.8 and 50 mM mercaptoethanol). This solution is dialysed overnight against two litres of this same buffer at 4°C.

### 2.b: Enzyme activity

The activity of each enzyme, as well as its 10 glyphosate resistance, is measured in vitro over 10 minutes at 37°C in the following reaction mixture: 100 mM maleic acid pH 5.6, 1 mM phosphoenolpyruvate, 3 mM shikimate 3-phosphate (prepared according to 15 Knowles P.F. and Sprinson D.B. 1970. Methods in Enzymol 17A, 351-352 from *Aerobacter aerogenes* strain ATCC 25597) and 10 mM potassium fluoride. The enzyme extract is added at the last moment after the addition of glyphosate, the final concentration of which varies from 0 to 20 mM.

20 The activity is measured by assaying the phosphate liberated according to the technique of Tausky H.A. and Shorr E. 1953. J. Biol. Chem. 202, 675-685.

Under these conditions, the wild-type (WT) 25 enzyme is already 85% inhibited at a glyphosate concentration of 0.12 mM. At this concentration, the mutant enzyme known as Ser106 is only 50% inhibited, and the other three mutants, Ile102, Ile102/Ser106 and

Ala101/Ile102, show little or no inhibition.

The glyphosate concentration has to be multiplied by ten, that is to say 1.2 mM, in order to produce a 50% inhibition of the mutant enzyme Ile102, 5 the mutants Ile102/Ser106, Ala/Ile and Ala still not being inhibited.

It should be noted that the activity of the mutants Ala/Ile and Ala is not inhibited up to 10 glyphosate concentrations of 10mM, and that that of the mutant Ile102/Ser106 is not reduced even if the glyphosate concentration is multiplied by 2, that is to say 20 mM.

Example 3:

Resistance of transformed tobacco plants

15 1-1- Transformation

The vector pRPA-RD-173 is introduced into *Agrobacterium tumefaciens* strain KHA101 (Hood et al., 1987) carrying the cosmid pTVK291 (Komari et al., 1986). The transformation technique is based on the 20 procedure of Horsch et al. (1985).

1-2- Regeneration

The regeneration of PBD6 tobacco (source SEITA France) from leaf explants is carried out on a Murashige and Skoog (MS) basal medium comprising 30 g/l 25 of sucrose as well as 200 µg/ml of kanamycin. The leaf explants are removed from plants cultivated in the greenhouse or in vitro and are transformed according to the leaf disc technique (Science, 1985, Vol. 227, pp.

1229-1231) in three successive steps: the first comprises the induction of shoots on a medium supplemented with 30 g/l of sucrose containing 0.05 mg/l of naphthylacetic acid (NAA) and 2 mg/l of 5 benzylaminopurine (BAP) for 15 days. The shoots formed during this step are then developed for 10 days by culturing on an MS medium supplemented with 30 g/l of sucrose but not containing any hormone. Shoots which have developed are then removed and cultured on an MS 10 rooting medium having half the content of salts, vitamins and sugar and not containing any hormone. After approximately 15 days, the rooted shoots are transferred to soil.

### 1-3- Glyphosate resistance

15 Twenty transformed plants were regenerated and transferred to the greenhouse for the construction of pRPA-RD-173. These plants were treated in the greenhouse at the 5-leaf stage with an aqueous suspension of RoundUp corresponding to 0.8 kg of 20 glyphosate active substance per hectare.

The results correspond to the observation of phytotoxicity indices recorded 3 weeks after treatment. Under these conditions, it is found that the plants transformed with the construction pRPA-RD-173 display 25 very good tolerance, whereas the untransformed control plants are completely destroyed.

These results show clearly the improvement brought about by the use of a chimeric gene according

to the invention for the same gene coding for  
glyphosate tolerance.

Example 4:

Transformation and selection of maize cells

5           BMS (Black Mexican Sweet) maize cells in an exponential growth phase are bombarded with the construction pRPA-RD-130 according to the principle and the protocol described by Klein et al. 1987 (Klein T.M., Wolf E.D., Wu R. and Sandford J.C. (1987): High 10 velocity microprojectiles for delivering nucleic acids into living cells, NATURE Vol. 327 pp. 70-73).

Two days after bombardment, the cells are transferred to the same medium containing 2 mM N-(phosphonomethyl)glycine.

15           After 8 weeks of selection on this medium, calluses which develop are selected, then amplified and analysed by PCR, and reveal clearly the presence of the chimeric OTTP-EPSPS gene.

20           Cells not bombarded and grown on the same medium containing 2 mM N-(phosphonomethyl)glycine are blocked by the herbicide and do not develop.

25           The transformed plants according to the invention may be used as parents for obtaining lines and hybrids having the phenotypic character corresponding to the expression of the chimeric gene introduced.

Description of the constructions of the  
plasmids

pRPA-RD-124: Addition of a "nos"  
polyadenylation signal to pRPA-ML-720 with creation of  
5 a cloning cassette containing the maize double mutant  
EPSPS gene (Thr 102 → Ile and Pro 106 → Ser). pRPA-ML-  
720 is digested with HindIII and treated with the  
Klenow fragment of *E. coli* DNA polymerase I to produce  
a blunt end. A second digestion is performed with NcoI,  
10 and the EPSPS fragment is purified. The EPSPS gene is  
then ligated with purified pRPA-RD-12 (a cloning  
cassette containing the polyadenylation signal of  
nopaline synthase) to give pRPA-RD-124. To obtain the  
useful purified vector pRPA-RD-12, it was necessary for  
15 the latter to be digested beforehand with SalI, treated  
with Klenow DNA polymerase and then digested a second  
time with NcoI.

pRPA-RD-125: Addition of an optimized transit  
peptide (OTP) to pRPA-RD-124 with creation of a cloning  
20 cassette containing the EPSPS gene targeted on the  
plasmids. pRPA-RD-7 (European Patent Application  
EP 652 286) is digested with SphI, treated with T4 DNA  
polymerase and then digested with SpeI, and the OTP  
fragment is purified. This OTP fragment is cloned into  
25 pRPA-RD-124 which has previously been digested with  
NcoI, treated with Klenow DNA polymerase to remove the  
protruding 3' portion and then digested with SpeI. This  
clone is then sequenced in order to ensure correct

translational fusion between the OTP and the EPSPS gene. pRPA-RD-125 is then obtained.

PRPA-RD-130: Addition of the H3C4 maize histone promoter and of adhl intron 1 sequences of pRPA-RD-123 (Patent Application EP 507 698) to pRPA-RD-125 with creation of a cassette for expression in plants for the expression of the double mutant EPSPS gene in the tissues of monocotyledons. pRPA-RD-123 (a cassette containing the H3C4 maize histone promoter fused with the adhl intron 1) is digested with NcoI and SacI. The DNA fragment containing the promoter derived from pRPA-RD-123 is then purified and ligated with pRPA-RD-125 which has previously been digested with NcoI and SacI.

PRPA-RD-159: Addition of the H4A748 *Arabidopsis* histone double promoter (Patent Application EP 507 698) to pRPA-RD-125 with creation of a cassette for expression in plants for the expression of the "OTP-double mutant EPSPS gene" gene in the tissues of dicotyledons. pRPA-RD-132 (a cassette containing the H4A748 double promoter (Patent Application EP 507 698)) is digested with NcoI and SacI. The purified promoter fragment is then cloned into pRPA-RD-125 which has been digested with EcoI and SacI.

PRPA-RD-173: Addition of the "H4A748 promoter-OTP-double mutant EPSPS gene" gene of pRPA-RD-159 to plasmid pRPA-BL-150A (European Patent Application 508 909) with creation of an Agrobacterium

*tumefaciens* transformation vector. pRPA-RD-159 is digested with NotI and treated with Klenow polymerase. This fragment is then cloned into pRPA-BL-150A with SmaI.

29  
SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Lebrun, Michel  
Sailland, Alain  
Freyasinet, Georges  
DeGryse, Eric

(ii) TITLE OF INVENTION: Mutated 5-enolpyruvylshikimate-3-phosphate synthase,  
gene coding for this protein and transformed plants containing this gene

(iii) NUMBER OF SEQUENCES: 5

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Connolly, Bove, Lodge and Hutz  
(B) STREET: 1220 Market Street  
(C) CITY: Wilmington  
(D) STATE: Delaware  
(E) COUNTRY: U.S.A.  
(F) ZIP: 19899

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE:  
(B) COMPUTER:  
(C) OPERATING SYSTEM:  
(D) SOFTWARE:

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:  
(B) FILING DATE:  
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: PCT/FR96/01125  
(B) FILING DATE: 18-JUL-1996

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Robert G. McMorrow, Jr.

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (302) 658-9141  
(B) TELEFAX: (302) 658-5614

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1713 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iv) ORIGINAL SOURCE:

- (A) ORGANISM: Lee says
- (B) STRAIN: Black Mexican Sweet
- (C) TISSUE TYPE: Callus

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: lambda gt10
- (B) CLONE: pRPA-ML-711

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AATCAATTTG	ACACAGAAA	CAACTATGAC	CATGATTACG	AATTCGGGCC	CGGGCGCGTG	60
ATCCGGCGGC	GGCACCGCGC	GCGGGGGTGC	ACGGCGGTGC	CGAGGAGATC	GTGCTGCAAC	120
CCATCAAGGA	GAATCTCGGGC	ACCTTCAGAC	TCCCCGGGTC	CAAGTGCGTT	TCCACCGGAA	180
TCTCTACT	GGGGGGCGTG	TCGGAGGGAA	CAACAGTGTT	TGATAACGTC	CTGAACACGT	240
AGGATGTC	CTACATGTC	GGGGGCTTGA	GGACTCTTGG	TCTCTCTGTC	GAACGGGACA	300
AACTGCGCA	AAACAGCTGA	GGTGGGGGCT	GTGTTGAAA	GGTCGCGTT	GAAGATGCTA	360
AAAGGAGA	CGACGCTTC	TTGGGGAATG	CTGGAACTGC	AATGGCGGCC	TTGACACGAG	420
CTGTTACTGC	TCTCTGGA	AACTGCACTT	ACGTCCTGAA	TGGAGTACCA	AGAATGAGGG	480

ATTAACCCAT TTTTAACTTC GTTTGTGAT TGAATCAACT TTTCAGAT GTTGATGTT 540  
 TCTTTCAC TAACTTCA CCTTGTGTC TCAATTAAT CGAAGGCTA CCTGCGCA 600  
 AAGTGAAGCT ATCAGCTTC ATCAAGCTTC AGTACTTAAAG TGCTTGTGTC ATGGCGCTC 660  
 TTTCAGCT TCAAGATTC GAGATTTAAA TCATTGATAA ATTAACTTCC ATTCGCTAC 720  
 TCGAAATGAC ATGGAGATT ATGGAGCTT TTGGTGTGAA AGCAGAGCA TGTGATAGT 780  
 CGGACAGATT CTACATTAAC GGAGGTCAAA AATACAGTC CCTAAATAAT GCCTATGTG 840  
 AACGTGATGC CTCAAGCGA AGCTATTTCT TGGCTGGTGC TCGAAATTACT GGAGGACTG 900  
 TGAATGTGGA AGTTTGTGGC ACCAGAATT TCGAAATGAA TGTGAAATTG GTGAGGTAC 960  
 TGGAGATGAT CGGAGCGAAG GTTACATGGA CGAGAGCTAG CGTAACATGTT ACTGGCCAC 1020  
 CGCGGGAGCC ATTTGGAGG AAACACCTCA AGGGGATTGA TGTCAACATG AACAGATAC 1080  
 CTGATGTCG CATGACTCTT GCTGTTGTTG CCTCTTTCG CGATGGCGCG AGACCCATCA 1140  
 GAGACGTGGC TTCTGGAGA GTAAAGGAGA CGAGAGGAT GGTTGGATC CGAGGGAGC 1200  
 TAACCAAGCT GGGAGCATCT GTTGAGGAGC GGCGGAGCTA CTGGCTCTTC AGCGCGCG 1260  
 AGAACGCAA CGTGCACCGC ATGGACACTT AGGAGGCC CAAGGATGCC ATGGCTTCTT 1320  
 CCTTGGCGC CTGTCGGAG CGCCGGCTCA CCTACCGGAA CCTGGGGTC ACCTGGAGA 1380  
 CCTTGGCGA CTACTTCGAT GTGCTGAGCA CTTTCCTCAA GAATTAATAA AGGGTGCAT 1440  
 ACTACCACGC AGCTTGTGATT AAGTGTGAGG CTGTTGCTGA GGAAATACAT TTCTTTGTT 1500  
 CTGTTTTCTT CTTCACCGG ATTAAAGTTT GAGTCCTGAA CCTTAGTGT TGTAGCAAG 1560  
 TTTCATTCG GGATCTTAAG TTTCGGACT GTAAAGCCAA TTTCATTCG AGAGTGGTC 1620  
 GTTGGAAATAA TAAGAATAAT AAATTACGT TGTGAAATAA AAAAATAAAA AAAAATAAAA 1680  
 AAAAATAAAA AAAAATAAAA AACCCGGGAA TTG 1713

## (2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 1340 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:  
 (A) ORGANISM: Zea mays  
 (B) STRAIN: Black Mexican Sweet

(viii) IMMEDIATE SOURCE:  
 (B) CLONE: pRPA-ML-716

(ix) FEATURE:  
 (A) NAME/KEY: CDS  
 (B) LOCATION: 6..1337

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CCATG GCC GGC RCC GAG GAG ATC GTC CTG CGG CCC ATC AAG GAG ATC	47
Ala Gly Ala Glu Glu Ile Val Leu Gln Pro Ile Lys Glu Ile	
1 3 10	
TCC GGC ACC GTC AAG CTG CGG GGG TCC AAG TCG CTT TCC AAC CGG ATC	95
Ser Gly Thr Val Lys Leu Pro Gly Ser Lys Ser Leu Ser Asn Arg Ile	
15 20 25 30	
CTC CTA CTC GCC GTC CTG TCC GAG GGG ATC ACA GTC GTT GAT AAC CTG	143
Leu Leu Leu Ala Ala Leu Ser Glu Gly Thr Thr Val Val Asp Asn Leu	
35 40 45	
CTG AAC AGT GAG GAT GTC CAC TAC ATG CTC CGG GCC TTG AGG ACT CTG	191
Leu Asn Ser Glu Asp Val His Tyr Met Leu Gly Ala Leu Arg Thr Leu	

50 55 60

GTT CTC TCT TTC GAA GGT GAC AAA CCT GCC AAA AGA AGT GTC GTC GTC Gly Leu Ser Val Glu Ala Asp Lys Ala Ala Lys Arg Ala Val Val Val 65 70 75	239
GTC TGT GTC GAA AAU TTC CCA GTC GAT GCT AAA GAG GAA GTG GAG Gly Cys Gly Lys Phe Pro Val Glu Asp Ala Lys Glu Glu Val Glu 80 85 90	247
CTG TTC TTG GGG AAT GCT GGA ACT GCA ATG CGG CCA TTG ACA GCA GGT Leu Phe Leu Gly Asn Ala Gly Thr Ala Met Arg Pro Leu Thr Ala Ala 95 100 105 110	335
GTT ACT GCT GCT GGT GGA AAT GCA ACT TAC GTG CTT GAT GGA GTA CCA Val Thr Ala Ala Gly Gly Asn Ala Thr Tyr Val Leu Asp Gly Val Pro 115 120 125	383
AGA ATG AGG GAG AGA CCC ATT GGC GAC TTG GTC GTC GGA TTG AAG CAG Arg Met Arg Glu Arg Pro Ile Gly XMP Leu Val Val Gly Leu Lys Gln 130 135 140	431
CTT GGT GCA GAT GTT GAT TGT TTC CTT GGC ACT GAC TGC CCA CCT GTT Leu Gly Ala Asp Val Asp Cys Phe Leu Gly Thr Asp Cys Pro Pro Val 145 150 155	479
CGT GTC AAT GGA ATC GGA GGG CTA CCT GGT GGC AAG GTC AAG CTG TCT Arg Val Asn Gly Ile Gly Gly Leu Pro Gly Gly Lys Val Lys Leu Ser 160 165 170	527
GGC TCC ATC AGC AGT CAG TAC TTG AGT GGC TTG CTC ATG GCT GCT CCT Gly Ser Ile Ser Ser Gln Tyr Leu Ser Ala Leu Leu Met Ala Ala Pro 175 180 185 190	575
TTG GCT CTT GGG GAT GTG GAG ATT GAA ATC ATT GAT AAA TTA ATC TCC Leu Ala Leu Gly Asp Val Glu Ile Glu Ile Asp Lys Leu Ile Ser 195 200 205	623
ATT CCG TAC GTC GAA ATG ACA TTG AGA TTG ATG GAG CCT TTT GGT GTG Ile Pro Tyr Val Glu Met Thr Leu Arg Leu Met Glu Arg Phe Gly Val 210 215 220	671
AAA GCA GAG CAT CCT GAT AGC TGG GAC AGA TTC TAC ATT AAG GGA GGT Lys Ala Glu His Ser Asp Ser Trp Asp Arg Phe Tyr Ile Lys Gly Gly 225 230 235	719
CAA AAA TAC AAG TCC CCT AAA AAT GGC TAT GTT GAA GGT GAT GAT GGC TCA Gln Lys Tyr Lys Ser Pro Lys Asn Ala Tyr Val Glu Gly Asp Ala Ser 240 245 250	767
AGC GCA AGC TAT TTC TTG GCT GGT GCT GCA ATT ACT GGA GGG ACT GTC Ser Ala Ser Tyr Phe Leu Ala Gly Ala Ile Thr Gly Gly Thr Val 255 260 265 270	815
ACT GTG GAA GGT TGT GGC ACC ACC AGT TTG CAG GGT GAT GTG AAG TTT Thr Val Glu Gly Cys Gly Thr Ser Leu Gln Gly Asp Val Lys Phe 275 280 285	863
GCT GAG GTC CTG GAG ATG ATG GCA GCG AAG GTC ACT TCG ACC GAG ACT Ala Glu Val Leu Glu Met Met Gly Ala Lys Val Thr Trp Thr Glu Thr 290 295 300	911
AGC GTC ACT GTT ACT GGC CCA CGG CGG GAG CCA TTT GGA AGG AAA CAC Ser Val Thr Val Thr Gly Pro Pro Arg Glu Pro Phe Gly Arg Lys His 305 310 315	959
CPC AAG GCG ATT GAT GTC AAC ATG AAC AAG ATG CCT GAT GTC GGC ATG Leu Lys Ala Ile Asp Val Asn Met Asn Lys Met Pro Asp Val Ala Met 320 325 330	1007
ACT CTT GCT GTC GTC GTC TTT GGC GAT GGC GCG ACA GCA GGC ATC AGA Thr Leu Ala Val Val Ala Leu Phe Ala Asp Gly Pro Thr Ala Ile Arg 335 340 345 350	1058
GAC GTG GCT TCC TGG AGA GTC AAG GAG ACC GAG AAG ATG GTT GCG ATC Asp Val Ala Ser Trp Arg Val Lys Glu Thr Glu Arg Met Val Ala Ile 355 360 365	1103
CGG ACG GAG CTA ACC AAG CTC GGA GCA TCT GTT GAG GAA GGG CGG GAC Arg Thr Glu Leu Thr Lys Leu Gly Ala Ser Val Glu Glu Gly Pro Asp	1151

TAC TCC ATC ATC ACT; CCG CGG; GAG CTG AAC GTG ACT GCG; ATG GAC  
 Tyr Cys Ile Ile Thr Pro Pro Glu Lys Leu Asn Val Thr Ala Ile Asp  
 384 390 396 400  
 1199

ACT; TAC GAC GAC CAC AGG ATG GCC ATG GCC TTC TCC CTT GCC CCC TGT  
 The Tyr Asp Asp His Arg Met Ala Met Ala Phe Ser Leu Ala Ala Cys  
 400 405 410 415  
 1249

GCC GAG GTC CCT GTC ACC ATC CGG GAC CCT GGG TGC ACC CGG AAG ACC  
 Ala Glu Val Pro Val Thr Ile Arg Asp Pro Gly Cys The Arg Lys Thr  
 415 420 425 430  
 1295

TTC CCC GAC TAC TTC GAT GTG CTG AGC ACT TTC GTC AAG AAT  
 Phe Pro Asp Tyr Phe Asp Val Leu Ser Thr Phe Val Lys Asn  
 435 440  
 1337

TAA 1340

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 444 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Ala Gly Ala Glu Glu Ile Val Leu Gln Pro Ile Lys Glu Ile Ser Gly  
 1 5 10 15

Thr Val Lys Leu Pro Gly Ser Lys Ser Leu Ser Asn Arg Ile Leu Leu  
 20 25 30

Leu Ala Ala Leu Ser Glu Gly Thr Thr Val Val Asp Asn Leu Leu Asn  
 35 40 45

Ser Glu Asp Val His Tyr Met Leu Gly Ala Leu Arg Thr Leu Gly Leu  
 50 55 60

Ser Val Glu Ala Asp Lys Ala Ala Lys Arg Ala Val Val Val Gly Cys  
 65 70 75 80

Gly Gly Lys Phe Pro Val Glu Asp Ala Lys Glu Glu Val Gln Leu Phe  
 85 90 95

Leu Gly Asn Ala Gly Thr Ala Met Arg Pro Leu Thr Ala Ala Val Thr  
 100 105 110

Ala Ala Gly Gly Asn Ala Thr Tyr Val Leu Asp Gly Val Pro Arg Met  
 115 120 125

Arg Glu Arg Pro Ile Gly Asp Leu Val Val Gly Leu Lys Gln Leu Gly  
 130 135 140

Ala Asp Val Asp Cys Phe Leu Gly Thr Asp Cys Pro Pro Val Arg Val  
 145 150 155 160

Asn Gly Ile Gly Gly Leu Pro Gly Gly Lys Val Lys Leu Ser Gly Ser  
 165 170 175

Ile Ser Ser Gln Tyr Leu Ser Ala Leu Leu Met Ala Ala Pro Leu Ala  
 180 185 190

Leu Gly Asp Val Glu Ile Glu Ile Asp Lys Leu Ile Ser Ile Pro  
 195 200 205

Tyr Val Glu Met Thr Leu Arg Leu Met Glu Arg Phe Gly Val Lys Ala  
 210 215 220

Ile His Ser Asp Ser Trp Asp Arg Phe Tyr Ile Lys Gly Gly Gln Lys  
 225 230 235 240

Tyr Lys Ser Pro Lys Asn Ala Tyr Val Glu Gly Asp Ala Ser Ser Ala  
 245 250 255

Ser Tyr Dhe Ile Ala Gly Ala Ala Ile Thr Gly Gly Thr Val Thr Val  
 260 265 270  
 Glu Gly Cys Gly Thr Thr Ser Leu Gin Gly Asp Val Lys Phe Ala Glu  
 275 280 285  
 Ile Gln Glu Met Met Gly Ala Lys Val Thr Trp Thr Glu Thr Ser Val  
 290 295 300  
 Thr Val Thr Gly Pro Pro Arg Glu Pro Phe Gly Arg Lys His Leu Lys  
 305 310 315 320  
 Ala Ile Asp Val Asn Met Asn Lys Met Pro Asp Val Ala Met Thr Leu  
 325 330 335  
 Ala Val Val Ala Leu Phe Ala Asp Gly Pro Thr Ala Ile Arg Asp Val  
 340 345 350  
 Ala Ser Trp Arg Val Lys Glu Thr Glu Arg Met Val Ala Ile Arg Thr  
 355 360 365  
 Glu Leu Thr Lys Leu Gly Ala Ser Val Glu Glu Gly Pro Asp Tyr Cys  
 370 375 380  
 Ile Ile Thr Pro Pro Glu Lys Leu Asn Val Thr Ala Ile Asp Thr Tyr  
 385 390 395 400  
 Asp Asp His Arg Met Ala Met Ala Phe Ser Leu Ala Ala Cys Ala Glu  
 405 410 415  
 Val Pro Val Thr Ile Arg Asp Pro Gly Cys Thr Arg Lys Thr Phe Pro  
 420 425 430  
 Asp Tyr Phe Asp Val Leu Ser Thr Phe Val Lys Asn  
 435 440

## (2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1340 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
- (A) ORGANISM: *Sus scrofa*
- (B) STRAIN: Black Mexican Sweet

- (viii) IMMEDIATE SOURCE:
- (B) CLONE: pRPA-ML-720

- (ix) FEATURE:
- (A) NAME/KEY: CDS
- (B) LOCATION: 6..1337

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CCATG GCG GCG GCG GAG GAG ATC GTG CTG CAG CCC ATC AAG GAG ATC	47
Ala Gly Ala Glu Glu Ile Val Leu Gin Pro Ile Lys Glu Ile	
1 5 10	
TCC GCG ACC GTC AAG CTG CGG GGG TCC AAG TCG CTT TCC AAC CGG ATC	95
Ser Gly Thr Val Lys Leu Pro Gly Ser Lys Ser Leu Ser Asn Arg Ile	
15 20 25 30	
CTC CTA CTC GCC GCC CTG TCC GAG CGG ACA ACA GTG GTT GAT AAC CTG	143
Leu Leu Leu Ala Ala Ser Glu Gly Thr Thr Val Val Asp Asn Leu	
35 40 45	
CTG AAC AGT GAG GAT GTC CAC TAC ATG CTC CGG GCC TTG AGG ACT CTT	181
Leu Asn Ser Glu Asp Val His Tyr Met Leu Gly Ala Leu Arg Thr Leu	
50 55 60	
GGT CTC TCT GTC GAA CGG GAC AAA GCT GCG AAA AGA GCT GTA GTT GTT	239
Gly Leu Ser Val Glu Ala Asp Lys Ala Ala Lys Arg Ala Val Val Val	
65 70 75	

GAC TTT GAT GAA AAC TTC GCA GTT GAT GAT AAA GAG GAA GTC CAG Gly Cys Gly Glu Lys Phe Pro Val Glu Asp Ala Lys Glu Glu Val Glu 400 415 430	287
TTC TTG TCG GGG AAC GCT GAA ATC GCA ATT GCA TCC TTT ACA GCA GCT Leu Phe Leu Gly Ala Gly Ile Ala Met Arg Ser Ile Thr Ala Ala 395 400 405 410 415 420 425 430 435 440	335
GTT ACT GCT GCT GGT GGA AAT GCA ACT TAC GTG CTT CAT GGA GAA GCA Val Thr Ala Ala Gly Gly Asn Ala Thr Tyr Val Leu Asp Gly Val Pro 115 120 125	383
AGA ATG AGG GAG AGA CGC ATT GGC GAC TTG GTT GTC GGA TTG AAG CAG Arg Met Arg Glu Arg Pro Ile Gly Asp Leu Val Val Gly Leu Lys Glu 130 135 140	431
CTT GGT GCA GAT GTT GAT TGT TTG CTT GGC ACT GAC TGC CCA CCT GTT Leu Gly Ala Asp Val Asp Cys Phe Leu Gly Thr Asp Cys Pro Pro Val 145 150 155	479
GCT GTC AAT GGA ATC GGA GGG CTA CCT GGT GGC AAG GTC AAG CTG TCT Arg Val Asn Gly Ile Gly Leu Pro Gly Gly Lys Val Lys Leu Ser 160 165 170	527
GGC TCC ATC AGC AGT CAG TAC TTG AGT GCC TTG CTG ATG GCT GCT CCT Gly Ser Ile Ser Ser Glu Tyr Leu Ser Ala Leu Leu Met Ala Ala Pro 175 180 185 190	575
TTG GCT CTT GGG GAT GTG GAG ATT GAA ATC ATT GAT AAA TTA ATC TCC Leu Ala Leu Gly Asp Val Glu Ile Glu Ile Asp Lys Leu Ile Ser 195 200 205	623
ATT CGG TAC GTC GAA ATG ACA TTG AGA TTG ATG GAG CGT TTT GGT GTG Ile Pro Tyr Val Glu Met Thr Leu Arg Leu Met Glu Arg Phe Gly Val 210 215 220	671
AAA GCA GAG CAT TCT GAT AGC TGG GAC AGA TTG TAC ATT AAG GGA GGT Lys Ala Glu His Ser Asp Ser Trp Asp Arg Phe Tyr Ile Lys Gly Gly 225 230 235	719
CAA AAA TAC AAG TCC CCT AAA AAT GCC TAT GTT GAA GGT GAT GGC TCA Gln Lys Tyr Lys Ser Pro Lys Asn Ala Tyr Val Glu Gly Asp Ala Ser 240 245 250	767
AGC GCA AGC TAT TTC TTG GCT GGT GCA ATT ACT GGA GGG ACT GTG Ser Ala Ser Tyr Phe Leu Ala Gly Ala Ala Ile Thr Gly Gly Thr Val 255 260 265 270	815
ACT GTG GAA GGT TGT GGC ACC ACC AGT TTG CAG GGT GAT GTG AAG TTT Thr Val Glu Gly Cys Gly Thr Thr Ser Leu Gln Gly Asp Val Lys Phe 275 280 285	863
GCT GAG GTC CTG GAG ATG ATG GGA CGG AAG GTT ACA TGG ACC GAG ACT Ala Glu Val Leu Glu Met Met Gly Ala Lys Val Thr Trp Thr Glu Thr 290 295 300	911
AGC GTC ACT GTT ACT GGC CCA CGG CAG CCA TTT GGG AGG AAA CAC Ser Val Thr Val Thr Gly Pro Pro Arg Glu Pro Phe Gly Arg Lys His 305 310 315	959
CTC AAG GCG ATT GAT GTC AAC ATG AAC AAG ATG CCT GAT GTC GCC ATG Leu Lys Ala Ile Asp Val Asn Met Asn Lys Met Pro Asp Val Ala Met 320 325 330	1007
ACT CTT GCT GTG GTT GCG CTC TTT GGC GAT GGC CGG ACA GCA GCC ATC AGA Thr Leu Ala Val Val Ala Leu Phe Ala Asp Gly Pro Thr Ala Ile Arg 335 340 345 350	1055
GAC GTC GCT TCC TGG AGA GTC AAG GAG ACC CGG AAG ATG GTT GCG ATC Asp Val Ala Ser Trp Arg Val Lys Glu Thr Glu Arg Met Val Ala Ile 355 360 365	1103
CAG ACG GAG CTA ACC AAG CTG GGA GCA TCT GTT GAG GAA GGG CGG GAC Arg Thr Glu Leu Thr Lys Leu Gly Ala Ser Val Glu Glu Gly Pro Asp 370 375 380	1151
TAC TGC ATC ATC AGC CGG CGG GAG AAC CTG AAC GTG AGC CGG ATC GAC Tyr Cys Ile Ile Thr Pro Pro Glu Lys Leu Asn Val Thr Ala Ile Asp 385 390 395	1199

ACG TAC GAC GAC CAC AAG ATG GCG ATG GCG TTC TGC CCC CCC TGT Thr Tyr Asp Asp Lys Arg Met Ala Met Ala Phe Ser Leu Ala Ala Cys 100 105 110	1247
GCT GAG GTC CCC GTC ACC ATC CCA GAC CCT GAG TCC ACC CGG AAG ACC Asp Glu Val Pro Val Thr Ile Arg Asp Pro Gly Cys Thr Arg Lys Thr 115 120 125 130	1295
TTC CCC GAC TAC TTC GAT GTG CTG AGC ACT TTC GTC AAG AAT Phe Pro Asp Tyr Phe Asp Val Leu Ser Thr Phe Val Lys Asn 135 140	1337
TAA	1340

## (2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 444 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Ala Gly Ala Glu Glu Ile Val Leu Gln Pro Ile Lys Glu Ile Ser Gly  
 1 5 10 15

Thr Val Lys Leu Pro Gly Ser Lys Ser Leu Ser Asn Arg Ile Leu Leu  
 20 25 30

Leu Ala Ala Leu Ser Glu Gly Thr Thr Val Val Asp Asn Leu Leu Asn  
 35 40 45

Ser Glu Asp Val His Tyr Met Leu Gly Ala Leu Arg Thr Leu Gly Leu  
 50 55 60

Ser Val Glu Ala Asp Lys Ala Ala Lys Arg Ala Val Val Val Gly Cys  
 65 70 75 80

Gly Gly Lys Phe Pro Val Glu Asp Ala Lys Glu Glu Val Gln Leu Phe  
 85 90 95

Leu Gly Asn Ala Gly Ile Ala Met Arg Ser Leu Thr Ala Ala Val Thr  
 100 105 110

Ala Ala Gly Gly Asn Ala Thr Tyr Val Leu Asp Gly Val Pro Arg Met  
 115 120 125

Arg Glu Arg Pro Ile Gly Asp Leu Val Val Gly Leu Lys Gln Leu Gly  
 130 135 140

Ala Asp Val Asp Cys Phe Leu Gly Thr Asp Cys Pro Pro Val Arg Val  
 145 150 155 160

Asn Gly Ile Gly Leu Pro Gly Gly Lys Val Lys Leu Ser Gly Ser  
 165 170 175

Ile Ser Ser Gln Tyr Leu Ser Ala Leu Leu Met Ala Ala Pro Leu Ala  
 180 185 190

Leu Gly Asp Val Glu Ile Glu Ile Ile Asp Lys Leu Ile Ser Ile Pro  
 195 200 205

Tyr Val Glu Met Thr Leu Arg Leu Met Glu Arg Phe Gly Val Lys Ala  
 210 215 220

Glu His Ser Asp Ser Trp Asp Arg Phe Tyr Ile Lys Gly Gly Gln Lys  
 225 230 235 240

Tyr Lys Ser Pro Lys Asn Ala Tyr Val Glu Gly Asp Ala Ser Ser Ala  
 245 250 255

Ser Tyr Phe Leu Ala Gly Ala Ala Ile Thr Gly Gly Thr Val Thr Val  
 260 265 270

Glu Gly Cys Gly Thr Thr Ser Leu Gln Gly Asp Val Lys Phe Ala Glu  
 275 280 285

Val Leu Glu Met Met Gly Ala Lys Val Thr Trp Thr Glu Thr Ser Val  
 210 295 300  
 Thr Val Thr Gly Pro Pro Arg Glu Pro Phe Gly Arg Lys His Leu Lys  
 305 310 315 320  
 Ala Ile Asp Val Asn Met Asn Lys Met Pro Asp Val Ala Met Thr Leu  
 325 330 335  
 Ala Val Val Ala Leu Phe Ala Asp Gly Pro Thr Ala Ile Arg Asp Val  
 340 345 350  
 Ala Ser Trp Arg Val Lys Glu Thr Glu Arg Met Val Ala Ile Arg Thr  
 355 360 365  
 Glu Leu Thr Lys Leu Gly Ala Ser Val Glu Glu Gly Pro Asp Tyr Cys  
 370 375 380  
 Ile Ile Thr Pro Pro Glu Lys Leu Asn Val Thr Ala Ile Asp Thr Tyr  
 385 390 395 400  
 Asp Asp His Arg Met Ala Met Ala Phe Ser Leu Ala Ala Cys Ala Glu  
 405 410 415  
 Val Pro Val Thr Ile Arg Asp Pro Gly Cys Thr Arg Lys Thr Phe Pro  
 420 425 430  
 Asp Tyr Phe Asp Val Leu Ser Thr Phe Val Lys Asn  
 435 440

CLAIMS

1. DNA gene coding for a mutated 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS), characterized in that it comprises at least one threonine 102 → isoleucine substitution.
2. DNA gene according to claim 1, characterized in that it comprises, in addition, at least a second mutation in the EPSPS, different from the first mutation.
3. DNA gene according to claim 2, characterized in that it comprises, in addition, a mutation consisting of a substitution of proline 106 by serine.
4. DNA gene according to claim 2, characterized in that it comprises, in addition, a mutation consisting of a substitution of glycine 101 by alanine.
5. DNA gene according to one of claims 1 to 4, characterized in that it is of bacterial origin.
6. DNA gene according to claim 5, characterized in that it originates from a bacterium of the genus *Salmonella typhimurium*.
7. DNA gene according to one of claims 1 to 4, characterized in that it is of plant origin.
8. DNA gene according to claim 7, characterized in that it is of maize origin.
9. Mutated EPSPS protein, characterized in that it comprises at least one substitution of

threonine 102 by isoleucine.

10. Chimeric gene comprising a coding sequence as well as regulatory elements at positions 5' and 3' which are heterologous and capable of functioning in plants, characterized in that it comprises as coding sequence at least one sequence according to one of claims 1 to 8.

11. Chimeric gene according to claim 9, characterized in that it comprises a plant virus promoter.

12. Chimeric gene according to claim 10, characterized in that it comprises a plant promoter (e.g.  $\alpha$ -tubulin, histone, introns, actin, etc.).

13. Vector for the transformation of plants, characterized in that it comprises at least one gene according to one of claims 10 to 12.

14. Plant cell, characterized in that it comprises at least one gene according to one of claims 10 to 12.

20 15. Plant, characterized in that it is obtained by regeneration from a cell according to claim 14.

25 16. Method for the production of plants with improved tolerance to a herbicide having EPSP synthase as its target, characterized in that plant cells or protoplasts are transformed with a gene according to one of claims 1 to 8, and in that the transformed cells are subjected to a regeneration.

17. Method of treatment of plants with a herbicide having EPSPS as its target, characterized in that the herbicide is applied to plants according to claim 15.

5           18. Method according to claim 17, characterized in that glyphosate or a glyphosate precursor is applied.

## COMBINED DECLARATION AND POWER OF ATTORNEY

Attorney Docket No. 5500\*13  
RP/PCT-1

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of subject matter which is claimed and for which a patent is sought on the invention entitled **MUTATED 5-ENOL PYRUVYL SHIKIMATE-3-PHOSPHATE SYNTHASE, GENE CODING FOR SAID PROTEIN AND TRANSFORMED PLANTS CONTANING SAID GENE"**

the specification of which

(check one)  is attached hereto.

was filed on October 14, 1997 as  Application Serial No. 08/945,144

Express Mail No. \_\_\_\_\_, as Serial No. not yet known,  
and including all the amendments through the date hereof.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)	Priority Claimed		
<u>PCT/FR96/01125</u> (Number)	<u>PCT</u> (Country)	<u>18/7/96</u> (Day/Month/Year Filed)	<input checked="" type="checkbox"/> <input type="checkbox"/> Yes No
<u>95/08979</u> (Number)	<u>France</u> (Country)	<u>19/7/95</u> (Day/Month/Year Filed)	<input checked="" type="checkbox"/> <input type="checkbox"/> Yes No

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112. I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application

(Application Serial No.)	(Filing Date)	(Status) <small>(patented, pending, abandoned)</small>
<u> </u>	<u> </u>	<u> </u>
<u> </u>	<u> </u>	<u> </u>
<u> </u>	<u> </u>	<u> </u>

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

(13) Rudolf E. Hutz, Reg. No. 22,397; Harold Pezzner, Reg. No. 22,112; John D. Fairchild, Reg. No. 19,756; Richard M. Beck, Reg. No. 22,580; Paul E. Crawford, Reg. No. 24,397; Thomas M. Meshbesher, Reg. No. 25,083; Patricia Smink Rogowski, Reg. No. 33,791; Robert G. McMorrow, Jr., Reg. No. 30,962; Ashley I. Pezzner, Reg. No. 35,646; William E. McShane, Reg. No. 32,707; Mary W. Bourke, Reg. No. 30,982; Gerard M. O'Rourke, Reg. No. 39,794; Allan N. Kutzenco, Reg. No. 38,945, all of P.O. Box 2207, Wilmington, Delaware 19899-2007, my attorneys with full power of substitution and revocation.

Send Correspondence To: <b>Connolly and Hutz</b> P.O. Box 2207 Wilmington, Delaware 19899-2207		Direct Telephone Calls To: <b>(302) 658-9141</b>
<small>FULL NAME OF FIRST INVENTOR</small> <b>MICHEL LEBRUN</b> <small>RESIDENCE</small> 224 Rue de Saint-Cyr, 69009 LYON, France <i>FLX</i>		<small>INVENTOR'S SIGNATURE</small> <i>Michel Lebrun</i> <small>DATE</small> <i>December, 11th 1997</i> <small>CITIZENSHIP</small> France
<small>POST OFFICE ADDRESS</small> 224 Rue de Saint-Cyr, 69009 LYON, France		
<small>FULL NAME OF SECOND JOINT INVENTOR IF ANY</small> <b>ALAIN SAILLAND</b> <small>RESIDENCE</small> 38 Rue Albert Chalinel, 69009 LYON, France		<small>INVENTOR'S SIGNATURE</small> <i>Alain Sailland</i> <small>DATE</small> <i>December, 16<sup>th</sup> 1997</i> <small>CITIZENSHIP</small> France
<small>POST OFFICE ADDRESS</small> 38 Rue Albert Chalinel, 69009 LYON, France		
<small>FULL NAME OF THIRD JOINT INVENTOR IF ANY</small> <b>GEORGES FREYSSINET</b> <small>RESIDENCE</small> 21 Rue de Nervieux, 69450 ST CYR AU MONT D'OR, France <i>FLX</i>		<small>INVENTOR'S SIGNATURE</small> <i>Georges Freyssinet</i> <small>DATE</small> <i>December 15<sup>th</sup>, 1997</i> <small>CITIZENSHIP</small> France
<small>POST OFFICE ADDRESS</small> 21 Rue de Nervieux, 69450 ST CYR AU MONT D'OR, France		
<small>FULL NAME OF FOURTH JOINT INVENTOR IF ANY</small> <b>ERIC DEGRYSE</b> <small>RESIDENCE</small> 4 Rue des Alisiers, 67100 Strasbourg, France <i>FLX</i>		<small>INVENTOR'S SIGNATURE</small> <i>Eric Degryse</i> <small>DATE</small> <i>December, 27th 1997</i> <small>CITIZENSHIP</small> France
<small>POST OFFICE ADDRESS</small> 4 Rue des Alisiers, 67100 Strasbourg, France		
<small>FULL NAME OF FIFTH JOINT INVENTOR IF ANY</small> <small>RESIDENCE</small>		<small>INVENTOR'S SIGNATURE</small> <small>DATE</small> <small>CITIZENSHIP</small>
<small>POST OFFICE ADDRESS</small>		
<small>FULL NAME OF SIXTH JOINT INVENTOR IF ANY</small> <small>RESIDENCE</small>		<small>INVENTOR'S SIGNATURE</small> <small>DATE</small> <small>CITIZENSHIP</small>
<small>POST OFFICE ADDRESS</small>		

United States Patent & Trademark Office  
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

1. Application papers are not suitable for scanning and are not in compliance with 37 CFR 1.52 because:
  - All sheets must be the same size and either A4 (21 cm x 29.7 cm) or 8-1/2" x 11".  
Pages \_\_\_\_\_ do not meet these requirements.
  - Papers are not flexible, strong, smooth, non-shiny, durable, and white.
  - Papers are not typewritten or mechanically printed in permanent ink on one side.
  - Papers contain improper margins. Each sheet must have a left margin of at least 2.5 cm (1") and top, bottom and right margins of at least 2.0 cm (3/4").
  - Papers contain hand lettering.
2. Drawings are not in compliance and were not scanned because:
  - The drawings or copy of drawings are not suitable for electronic reproduction.
  - All drawings sheets are not the same size. Pages must be either A4 (21 cm x 29.7 cm) or 8-1/2" x 11".
  - Each sheet must include a top and left margin of at least 2.5 cm (1"), a right margin of at least 1.5 cm (9/16") and a bottom margin of at least 1.0 cm (3/8").
3. Page(s) \_\_\_\_\_ are not of sufficient clarity, contrast and quality for electronic reproduction.
4. Page(s) \_\_\_\_\_ are missing.
5. OTHER: 40 drawings enclosed